Blood test could revolutionize rectal cancer monitoring
NCT ID NCT05629442
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study looks at whether a blood test that finds tiny bits of tumor DNA (ctDNA) can help doctors monitor rectal cancer more closely than standard scans. Researchers will collect blood and tissue samples from 60 adults with non-spreading rectal cancer before and after standard treatments. The goal is to see if ctDNA can predict if the cancer is completely gone or if it comes back, potentially allowing some patients to avoid surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON METASTATIC RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mass General Cancer Center Newton-Wellesley Hospital
Newton, Massachusetts, 02462, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Which rectal cancer surgery preserves quality of life better? a study investigates
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- Can AI learn to grade endoscopy quality from video?
- Can precision protons spare rectal cancer patients from harsh side effects?
- A new radiation combo may spare the rectum in early cancer